IP Library Granted Patent US 12,171,772
Granted Patent B2
US 12,171,772 · App. 18/314,560 · Granted Dec 24, 2024

Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives

Inventors: Gavin Hirst (San Diego, CA); Raja Reddy (San Diego, CA); Scott J. Hecker (Del Mar, CA); Maxim Totrov (San Diego, CA); David C. Griffith (San Marcos, CA); Olga Lomovskaya (Mill Valley, CA); Michael N. Dudley (San Diego, CA); Serge Henri Boyer (San Diego, CA)
Assignee: MELINTA SUBSIDIARY CORP.
A61K31/69A61K9/0019A61K9/0053A61K31/407A61K31/4196A61K31/427A61K31/4439A61K31/546A61K45/06C07F5/025Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,171,772
App. No.
18/314,560
Granted
Dec 24, 2024
Kind
B2
Abstract

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Claims (5)

1. A crystalline form of 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid:

2. The crystalline form of claim 1 , wherein the crystalline form has an X-ray powder diffraction pattern comprising three or more characteristic peaks expressed in degrees two-theta to within 0.2° selected from 9.0°, 15.7°, 17.3°, 17.6°, 18.1°, 21.3°, 22.4°, 23.5°, 24.9°, 27.2°, 27.4°, 28.1°, 29.1°, 31.2°, and 35.7°.

3. The crystalline form of claim 1 , wherein the crystalline form has an X-ray powder diffraction pattern comprising characteristic peaks expressed in degrees two-theta to within 0.2° at 9.0°, 17.3°, and 18.1°.

4. The crystalline form of claim 1 , wherein the crystalline form has an X-ray powder diffraction pattern substantially identical to FIG. 3 .

5. The crystalline form of claim 1 or 2 , wherein the crystalline form has a melting point of about 155° C.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2024
From: HIRST, GAVIN; REDDY, RAJA; HECKER, SCOTT; TOTROV, MAXIM; GRIFFITH, DAVID C.; RODNY, OLGA; DUDLEY, MICHAEL N.; BOYER, SERGE
To: REMPEX PHARMACEUTICALS, INC.
Reel/Frame 069137/0840 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2024
From: REMPEX PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 069137/0961 →
CHANGE OF NAME Recorded Nov 5, 2024
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 069138/0030 →